Berengere Ouine
Overview
Explore the profile of Berengere Ouine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musiani D, Yucel H, Vallette M, Angrisani A, El Botty R, Ouine B, et al.
Mol Cell
. 2025 Feb;
PMID: 40010343
Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) is the major obstacle to their effectiveness in the treatment of homologous recombination (HR)-deficient (HRD) tumors. Hence, developing alternative treatments for HRD...
2.
Ben Brahim C, Courageux C, Jolly A, Ouine B, Cartier A, De La Grange P, et al.
Stem Cell Rev Rep
. 2021 Jan;
17(3):703-718.
PMID: 33495975
Slug/Snail2 belongs to the Epithelial-Mesenchymal Transition (EMT)-inducing transcription factors involved in development and diseases. Slug is expressed in adult stem/progenitor cells of several epithelia, making it unique among these transcription...
3.
Byron A, Bernhardt S, Ouine B, Cartier A, Macleod K, Carragher N, et al.
Sci Rep
. 2020 Dec;
10(1):21985.
PMID: 33319783
Reverse-phase protein array (RPPA) technology uses panels of high-specificity antibodies to measure proteins and protein post-translational modifications in cells and tissues. The approach offers sensitive and precise quantification of large...
4.
Gerossier L, Dubois A, Paturel A, Fares N, Cohen D, Merle P, et al.
Clin Res Hepatol Gastroenterol
. 2020 Nov;
45(5):101553.
PMID: 33183998
Background: A promising avenue for cancer treatment is exacerbating the deregulation of the DNA repair machinery that would normally protect the genome. To address the applicability of poly(ADP-ribose) polymerase (PARP)...
5.
Coussy F, Lavigne M, De Koning L, El Botty R, Nemati F, Naguez A, et al.
Theranostics
. 2020 Feb;
10(4):1531-1543.
PMID: 32042320
Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields only partial clinical benefits. In...
6.
Ouine B, Rajkumar S, Hupe P, De Koning L
Adv Exp Med Biol
. 2019 Dec;
1188:77-93.
PMID: 31820384
The analytic platform described in this chapter uses proteins extracted from cultured cells as an infinite source of material to set up, validate, and quality control an RPPA platform. Readout...
7.
De Koning L, Decaudin D, El Botty R, Nicolas A, Carita G, Schuller M, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31146482
Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with (BRCA1 associated protein) mutations. However, no data on DNA repair capacities in UM are available....
8.
Caruso S, Calatayud A, Pilet J, La Bella T, Rekik S, Imbeaud S, et al.
Gastroenterology
. 2019 May;
157(3):760-776.
PMID: 31063779
Background And Aims: Hepatocellular carcinomas (HCCs) are heterogeneous aggressive tumors with low rates of response to treatment at advanced stages. We screened a large panel of liver cancer cell lines...
9.
Coussy F, De Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, et al.
Int J Cancer
. 2019 Mar;
145(7):1902-1912.
PMID: 30859564
Triple-negative breast cancer (TNBC) represents 10% of all breast cancers and is a very heterogeneous disease. Globally, women with TNBC have a poor prognosis, and the development of effective targeted...
10.
El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely J, et al.
Oncotarget
. 2018 Jul;
9(51):29587-29600.
PMID: 30038706
Breast cancer is a complex disease in which each patient could present several genetic alterations that are therapeutically relevant in cancers. Here we explored the therapeutic benefit of combining PARP...